~~<i id='BFF4BA0EAB'><strike id='BFF4BA0EAB'><tt id='BFF4BA0EAB'><pre id='BFF4BA0EAB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：hotspot 2025-09-06 06:17:21 - browse：9429

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Anavex keeps shifting the goalposts in its clinical trials

focus

Wikipedia

explore

leisure time

AdobeDrugshortagesintheUnitedStatesareatarecordhigh.Atleast14essentialgenericcancerdrugsarecurrently

WSS

Baltimore teen accused of firing into crowd during block party mass shooting

For Cytokinetics, FDA rejection of heart drug would help, not hinder

FDA panel issues narrow recommendation for Covid vaccine booster doses

Cancer drug shortages' outsize impact on ovarian cancer patients

Maui's cultural, historic landmarks damaged in the devastating wildfires

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

knowledge

entertainment

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Man killed during FBI raid in connection with threats against Biden, other officials

Alkermes shareholders re

The pain doctors face in trying to build their families

As demand for Covid shots wanes, Moderna seeks its next success

FDA panel issues narrow recommendation for Covid vaccine booster doses

Jerome Adams on the need for new antivirals for Covid

Beware the threat of staffing cuts at the CDC

Anesthesiologist group: stop taking Ozempic before surgery

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Wikipedia

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Anavex keeps shifting the goalposts in its clinical trials

NIH trials fail to test meaningful long Covid therapies, experts say

The boys, now 6, who are gene therapy’s ‘edge case’ problem

A biotech analyst on neuroscience, placebo effect, not over

The pain doctors face in trying to build their families

Wikipedia

explore

leisure time

leisure time